Product Details
Product Name:
Zingiberen newsaponin |
CAS No.:
91653-50-8 |
Purity:
99.75% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Zingiberen newsaponin |
Description | Zingiberen newsaponin is a steroidal saponin from Dioscorea zingiberensis. |
In vitro | In the screening test on platelet aggregation, Zingiberen newsaponin exhibited an induction effect on platelet aggregation in vitro[1]. |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/ml (57.3 mM)
|
Keywords | Zingiberen newsaponin | inhibit | Inhibitor |
Inhibitors Related | 3-Aminobenzamide | Tauroursodeoxycholate | Olaparib |
Related Compound Libraries | Traditional Chinese Medicine Monomer Library | Bioactive Compound Library | Rare Natural Product Library | Selected Plant-Sourced Compound Library | Miao medicine Compound Library | Natural Product Library for HTS | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:55589-62-3
$35.00 / 1g
-
CAS:1203494-49-8
$37.00 / 2mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$0.00/5mg |
|
Shanghai Standard Technology Co., Ltd.
|
2020-03-30 |